Study in Pediatric Subjects With Peanut Allergy to Evaluate Efficacy and Safety of Dupilumab as Adjunct to AR101 (Peanut Oral Immunotherapy)
Clinical trial NCT03682770 · COMPLETED
Trial details
- NCT number
- NCT03682770
- Sponsor
- Regeneron Pharmaceuticals
- Status
- COMPLETED
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2018-10-03
- Primary completion
- 2020-10-16
- Enrollment
- 148
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.